All In Biotech

Free tool

FAERS Monitor: Differin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020748 or its brand name (Differin, Adapalene). Reports on generic versions are filed under their own applications.

Reports

6,328

Serious

864

14% of reports

Hospitalization

305

Death reported

25

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective2,537
  • dry skin941
  • skin burning sensation574
  • acne553
  • skin irritation535
  • erythema504
  • condition aggravated442
  • rash405
  • skin exfoliation352
  • therapy cessation227
  • pruritus205
  • hypersensitivity182
  • pain124
  • pain of skin118
  • inappropriate schedule of product administration90

Reports by year received

View as table
YearReports
200413
200512
200626
20079
200828
200926
201033
201178
201262
201358
201471
2015118
2016118
201772
201882
2019175
2020128
2021108
2022155
2023195
2024832
2025878
20263,051

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,831 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
skin irritationSignal53539.336.219,723
skin burning sensationSignal57426.824.814,186
acneSignal55324.422.512,348
dry skinSignal94123.622.220,319
therapy cessationSignal22714.813.02,892
pain of skinSignal11814.612.21,480
skin exfoliationSignal35213.912.64,208
erythemaSignal5048.27.53,186
drug ineffectiveSignal2,5376.46.212,325
condition aggravatedSignal4424.84.41,359
hypersensitivitySignal1823.32.8285
rashSignal4053.12.8582
pruritus2051.81.570
inappropriate schedule of product administration901.71.423
pain1240.70.620

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.